Products containing Olestra, the zero-calorie fat substitute, will no longer bear a label informing consumers of purported unpleasant gastrointestinal (GI) side effects. The Food and Drug Administration (FDA), after reviewing a six-week study that involved 3000 people, ruled that Olestra "caused only mild, infrequent GI effects," according to an FDA press release. The FDA also decided to continue the requirement for food manufacturers to add vitamins A, D, E, and K to counteract Olestra's effects on the absorption of these specific vitamins.
Products containing Olestra, the zero-calorie fat substitute, will no longer bear a label informing consumers of purported unpleasant gastrointestinal (GI) side effects. The Food and Drug Administration (FDA), after reviewing a six-week study that involved 3000 people, ruled that Olestra "caused only mild, infrequent GI effects," according to an FDA press release. The FDA also decided to continue the requirement for food manufacturers to add vitamins A, D, E, and K to counteract Olestra's effects on the absorption of these specific vitamins.